The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

There has been a "dramatic" decrease in cases of RSV among babies due to a new vaccine but flu is rising and expected to peak after Christmas, the interim chief medical officer said. Usually one in ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next year for nirsevimab, an antibody designed to prevent respiratory syncytial virus (RSV ...

Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...

IDWeek 2024 was held at the Los Angeles Convention Center in Downtown Los Angeles, CA, USA, from 16–19 October. Phoebe Hall ...

At a meeting to present its vaccines pipeline to investors today, the French pharma is highlighting the potential of Beyfortus (nirsevimab) for the protection of infants in their first RSV season ...

SummaryState warns of rising COVID threat, surge in Whooping Cough cases The Illinois Department of Public Health is ...

In recent months, soldiers have demolished more than 600 buildings to create a buffer area and expanded a network of bases, a New York Times analysis of satellite imagery and video footage shows ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.